Last reviewed · How we verify
NCT05677932
Bright Light Therapy for Post-COVID-19 Fatigue
NA trial testing Bright light therapy in Post COVID-19 Condition in 12 participants. Completed in 30 April 2024.
28 February 2024
Quick facts
| Lead sponsor | Chinese University of Hong Kong |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 15 February 2023 |
| Primary completion | 28 February 2024 |
| Estimated completion | 30 April 2024 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- Bright light therapy
- Dim red light therapy
Conditions studied
- Post COVID-19 Condition — all drugs for Post COVID-19 Condition →
Sponsor
Chinese University of Hong Kong
Who can join
18 and older, any sex, with Post COVID-19 Condition. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized placebo-controlled trial to examine the efficacy of two-week bright light therapy for patients with post-COVID-19 fatigue.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05677932
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Bright light therapy
Trials testing the same drug.
- NCT07002554 — Bright Light Therapy for Depressed Geriatric Inpatients · Phase 2 · enrolling by invitation
- NCT06973759 — Adjunctive Bright Light Therapy in Adolescents With Depression and Eveningness · NA · recruiting
- NCT05524961 — Bright Light Therapy for Non-motor Symptoms in Parkinson's Disease · NA · completed
- NCT06635928 — Bright Light Therapy in ME/CFS Patients · NA · completed
- NCT04949984 — Bright Light Therapy in Older Adults With Moderate to Very Severe Dementia · NA · completed
Other recruiting trials for Post COVID-19 Condition
Currently open trials in the same condition.
- NCT07110714 — Effects of Kneipp Hydrotherapy in Post-COVID-19 Patients · NA · recruiting
- NCT06156176 — Pursuing Reduction in Fatigue After COVID-19 Via Exercise and Rehabilitation (PREFACER): A Randomized Feasibility Trial · NA · recruiting
- NCT06766825 — Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC) · Phase 2 · recruiting
- NCT05946512 — MR-spectroscopy in Post-covid Condition Prior to and Following a Yoga Breathing Intervention · NA · recruiting
- NCT05890534 — Pycnogenol® in Post-COVID-19 Condition · Phase 3 · active not recruiting
Other Chinese University of Hong Kong trials
Trials by the same sponsor.
- NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
- NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
- NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
- NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
- NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05677932 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
- Last refreshed: 20 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05677932.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing